Your browser doesn't support javascript.
loading
Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect.
Lee, Seonhwa; Lee, Hae-June; Kang, Hyunji; Kim, Eun-Ho; Lim, Young-Cheol; Park, Hyejin; Lim, Sang Moo; Lee, Yong Jin; Kim, Jung Min; Kim, Jin Su.
Afiliación
  • Lee S; Division of RI application, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. remnant8724@naver.com.
  • Lee HJ; Department of Bio-convergence Engineering, Korea University, Seoul 02856, Korea. remnant8724@naver.com.
  • Kang H; Division of radiation biomedical research, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. hjlee@kirams.re.kr.
  • Kim EH; Division of RI application, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. hyunji.k0618@gmail.com.
  • Lim YC; Radiological and Medico-Oncological Sciences, University of Science and Technology, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. hyunji.k0618@gmail.com.
  • Park H; Department of Bio-convergence Engineering, Korea University, Seoul 02856, Korea. eh140149@kirams.re.kr.
  • Lim SM; Division of RI application, Korea Institute of Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. zerofe0701@gmail.com.
  • Lee YJ; Research support team, ANDIVA Inc., Chuncheon 24324, Korea. zerofe0701@gmail.com.
  • Kim JM; Department of Bio-convergence Engineering, Korea University, Seoul 02856, Korea. eh140149@kirams.re.kr.
  • Kim JS; Department of Nuclear Medicine, Korea Institute Radiological and Medical Sciences, 75 Nowon-ro, Nowon-gu, Seoul 01812, Korea. smlim328@kcch.re.kr.
J Clin Med ; 8(2)2019 Feb 11.
Article en En | MEDLINE | ID: mdl-30754707
ABSTRACT
The authors identified that chemo-brain was induced after trastuzumab (TZB) therapy. In addition, atorvastatin (ATV) could rescue chemo-brain during trastuzumab (TZB) therapy. Enhanced therapeutic effect of TZB was confirmed after ATV therapy. We also investigated that there was no hair loss side effect due to ATV therapy. In an animal model, 150 µg TZB and five serial doses of 20 mg/kg ATV were administered. 18F-fluorodeoxyglucose Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) data were acquired. Statistical parametric mapping analysis and voxel-based morphometry analysis were performed to identify differences in glucose metabolism and gray matter concentration. The enhanced therapeutic efficacy of TZB after ATV treatment was assessed using a human epidermal growth factor receptor 2-positive gastric cancer model. We found a decrease in cerebral glucose metabolism and gray matter concentration in the frontal lobe following TZB therapy (p < 0.005). After subsequent ATV administration, glucose metabolism and regional gray matter concentration were rescued (p < 0.005). Cognitive impairment due to TZB and the rescue effect of ATV were confirmed using a passive avoidance test and quantitative real-time reverse transcription PCR. Furthermore, the penetration and accumulation of TZB in tumors increased by 100% after ATV co-administration, which resulted in an enhanced anti-cancer effect. Our study collectively demonstrates that ATV co-administration with TZB rescued the TZB-induced chemo-brain and enhances the therapeutic efficacy of TZB in tumors. We also showed that there was no hair loss during ATV therapy.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Clin Med Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Clin Med Año: 2019 Tipo del documento: Article